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Abstract
Seasonal influenza is caused by two influenza A subtype (H1N1 and H3N2) and two influ-
enza B lineage (Victoria and Yamagata) viruses. Of these antigenically distinct viruses, the
H3N2 virus was consistently detected in substantial proportions in Korea during the 2010/
11-2013/14 seasons when compared to the other viruses and appeared responsible for the
influenza-like illness rate peak during the first half of the 2011/12 season. To further scruti-
nize possible causes for this, we investigated the evolutionary and serological relationships
between the vaccine and Korean H3N2 strains during the 2011/12 season for the main anti-
genic determinants of influenza viruses, the hemagglutinin (HA) and neuraminidase (NA)
genes. In the 2011/12 season, when the number of H3N2 cases peaked, the majority of the
Korean strains did not belong to the HA clade of A/Perth/16/2009 vaccine, and no Korean
strains were of this lineage in the NA segment. In a serological assay, post-vaccinated
human sera exhibited much reduced hemagglutination inhibition antibody titers against the
non-vaccine clade Korean H3N2 strains. Moreover, Korean strains harbored several amino
acid differences in the HA antigenic sites and in the NA with respect to vaccine lineages dur-
ing this season. Of these, the HA antigenic site C residues 45 and 261 and the NA residue
81 appeared to be the signatures of positive selection. In subsequent seasons, when H3N2
cases were lower, the HA and NA genes of vaccine and Korean strains were more phyloge-
netically related to each other. Combined, our results provide indirect support for using phy-
logenetic clustering patterns of the HA and possibly also the NA genes in the selection of
vaccine viruses and the assessment of vaccine effectiveness.
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Introduction
Influenza virus is a RNA virus that belongs to the family Orthomyxoviridae [1]. Four anti-
genically different viruses, the H1N1 and H3N2 subtypes of influenza A virus (IAV) and the
Victoria and Yamagata lineages of influenza B virus (IBV), cause seasonal epidemics among
humans [2, 3]. Vaccines can reduce seasonal influenza-related mortality and morbidity [4,
5]. Due to the continuous accumulation of genetic changes in the virus proteins most read-
ily recognized by the immune system, a phenomenon referred to as antigenic drift [6], there
is a need to frequently update vaccines in order to guarantee their effectiveness [7, 8].
Which viruses are likely well-suited for use as vaccine strains is announced by the World
Health Organization (WHO) in February and September each year for the countries in the
Northern and Southern Hemispheres, respectively [9]. These recommendations follow on a
comprehensive process of surveillance and serological evaluation of thousands of contem-
porary virus strains in cooperation with National Influenza Centers of WHO member states
and Collaborating Centers [10]. Yet, despite the assiduous efforts of WHO, there is some-
times a mismatch between the vaccine and circulating strains leading to reduced vaccine
effectiveness [11], as was observed for the H3N2 virus during the 2011/12 H3N2 seasonal
influenza [12–16]. Moreover, the number of viral isolates of seasonal influenza viruses and
clinical manifestations defined in influenza-like illness (ILI) patients [17, 18] indicate that
the H3N2 virus had more pronounced impact on influenza epidemiology in Korea during
this season.
The degree of antigenic drift can be quantified with a hemagglutinin inhibition (HI) assay
[19, 20]. Because HI assay results are key in deciding which lineages should be included in the
next season’s vaccine, it is critical that the HI assay results accurately mirror the true antigenic
distance between the compared strains. However, for reasons that are not completely under-
stood but that are likely grounded in different influenza infection and/or immunization histo-
ries, the HI assay results based on standard ferret antisera do not always agree with those
obtained when human antisera are used [21, 22].
Recent theoretical and computational modeling developments spurred hopes for bypass-
ing the difficulties characteristic for the in vitro determination of a strain’s suitability as a
vaccine candidate with in silico analyses that only capitalize on the virus genetic data [23–
25]. A key criterion common to all in silico methods is how the candidate vaccine clusters
among other circulating strains in a phylogenetic tree. Perhaps not surprising, these studies
focus only on the HA gene. However, the NA gene encodes another surface glycoprotein of
influenza viruses, which is one of the two main antigens that induce antibody-mediated
immune responses [26, 27]. In addition, given that the functional balance between the HA
and NA proteins that initiates and terminates the reproductive cycle of influenza virus
infection, respectively, is of importance in terms of viral fitness [1, 28, 29], the phylogenetic
clustering patterns of the NA gene should be also considered for the selection of vaccine
viruses.
In this study, we first investigated the correlation between the ILI incidence rates and the
number of influenza isolates in Korea during the 2010/11-2013/14 seasons. To scrutinize the
positive correlation between the peak of ILI rates and H3N2 circulation in the 2011/12 season,
we investigated the evolutionary and serological relationships between the HA and NA genes
of vaccine and contemporary Korean H3N2 strains in the 2011/12 season as well as in the sub-
sequent two seasons. We also determined which amino acid changes in the trunk lineages of
HA and NA phylogenetic trees were positively selected.
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Materials and methods
Viral genetic sequences
For the analysis focusing on the HA and NA clustering patterns of H3N2 stains during the
2011/12 season, Korean sequences from the 2011/12 season were obtained from viral isolates
(n = 21) of nasopharyngeal clinical samples that were collected in Korea University Medical
Center (KUMC) Guro Hospital, or were downloaded from the Korea Influenza Sequence and
Epitope Database (KISED; http://influenza.cdc.go.kr/home/w) (n = 154). These were comple-
mented with reference sequences of the 2009/10-2011/12 seasons downloaded from the data-
bases of National Center for Biotechnology Information (NCBI, https://www.ncbi.nlm.nih.
gov/genomes/FLU/FLU.html) (n = 451) and of Global Initiative on Sharing All Influenza Data
(GISAID, http://platform.gisaid.org/epi3/frontend#4b03b7) (n = 8). The HA and NA data sets
were aligned using MAFFT [30, 31]. The nucleotide lengths of the aligned HA and NA data
sets were 987 (nucleotide residues 49–1,035) and 1,407 (nucleotide residues 1–1,407), respec-
tively (S1 Data).
For the analysis focusing on the 2010/11 and 2013/14 clustering patterns, an additional 25
KUMC HA and NA sequences (total n = 46: 2011/12 season, 21; 2012/13, 3; and 2013/14, 22)
were included along with 21 sequence sets of the 2011/12 season. Reference sequences were
again obtained from the NCBI (n = 1,810) and GISAID (n = 178) databases. To remove a pos-
sible bias caused by a number of Korean sequences, however, the KISED sequences were not
included in this analysis. As a result, a total of 2,034 full-length HA and NA sequences (S1
Data) were then aligned using the same MATTF program (v7.130b) [30].
ILI incidence rates and the number of isolates of seasonal influenza
viruses in Korea
Information of the ILI incidence rates and the number of seasonal influenza viruses isolates
detected in Korea was collected from the weekly updates of KCDC reporting the nation-wide
activity of influenza viruses [18]. The collected data of the 2010/11-2013/14 seasons were then
summarized by virus type or subtype on a weekly basis from September (approximately week
35) through June (approximately week 26).
Phylogenetic study and evolutionary rates
Evolutionary relationships of the H3N2 HA and NA genetic sequences were inferred with the
Markov Chain Monte Carlo (MCMC) sampling method implemented in BEAST (v1.8.2) [32].
The substitution process was modeled with a GTR+I+Γ model [33]. A relaxed molecular clock
with rates drawn from a lognormal distribution was specified [34], and the skygrid was set as a
flexible tree prior [35]. MCMC chains ran for 2 x 108 iterations and were sampled every 2 x 105
iterations. 10% of the chain length was removed as burn-in. Convergence and mixing proper-
ties of at least two independent chains per gene were assessed in Tracer (v1.6) (http://tree.bio.
ed.ac.uk/software/tracer/). Maximum clade credibility trees were built using TreeAnnotator
(v1.8.2) and visualized using FigTree (v1.4.2) (http://tree.bio.ed.ac.uk/software/figtree/). For
synonymous and nonsynonymous substitution rates, independent MCMC runs were addi-
tionally analyzed with the same prior setting using tailor-made scripts.
Positive selection profiles
Positive selection profiles acting upon the HA and NA genes were first assessed using the web
server of Datamonkey (http://www.datamonkey.org) [36] and confirmed using the HyPhy
Phylogenetic discordance between influenza vaccine and Korean H3N2 strain genes
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package (v2.2) [37]. Site-specific, positive selection profiles were then determined based on the
estimated ratios of nonsynonymous (dN) to synonymous substitutions (dS) at every codon by
the single likelihood ancestor counting method using a REV nucleotide substitution model
[38]. The cutoff value was ‘p< 0.05’.
Hemagglutination inhibition (HI) assay
For use in a HI assay, we isolated 12 H3N2 strains from nasopharyngeal clinical specimens
collected from outpatients who visited KUMC Guro Hospital in the 2011–12 season. A
H3N2 vaccine virus X-187 (NIBSC code: 11/108) was provided by Green Cross Corporation
(Yongin, Republic of Korea). A vaccine prototype A/Victoria/210/2009 virus was provided
by Korea Centers for Disease Control and Prevention (KCDC, Osong, Republic of Korea).
X-187/HA:T228S was generated by reverse genetics using the genetic plasmids of X-187
that were constructed into an ambisense pDZ plasmid [39]. The pDZ/HA:T228S plasmid
was prepared by a site-directed mutagenesis (Stratagene, La Jolla, CA) according to the
manufacturer’s instruction. All the viruses were purified by a plaque assay in Madin-Darby
canine kidney (MDCK) cells and propagated in 9–10 days old embryonated chicken eggs.
The MDCK cell was obtained from America Type Culture Collection (Manassas, VA) and
maintained with EMEM (Lonza, Basel, Switzerland). Using the plaque-purified and egg-
propagated viruses, we analyzed viral genetic sequences after reverse transcription PCR.
HA units of each virus were determined by a hemagglutination assay using 0.5% (v/v) tur-
key RBC (tRBC). For a HI assay, we used 80 post-vaccinated patient sera, which were col-
lected after 4–5 weeks post-vaccination in KUMC Guro Hospital in the 2011–12 season. To
remove nonspecific inhibitors [40], the sera were treated with receptor-destroying enzyme
(Denka Seiken, Tokyo, Japan). The RDE-treated sera were then two-fold diluted serially in
25 μl PBS and mixed with 4 HA units of a virus (in 25 μl). After one hour incubation at
37˚C, 50 μl of 0.5% (v/v) tRBC was added to each virus-sera mixture and incubated 30–45
minutes at room temperature. HI antibody titers of the sera were determined as the highest
dilution that showed complete inhibition of hemagglutination in duplicate experiments.
This study was approved by the Korea University Guro Hospital Institutional Review Board
(approval number: KUGH 13210–002).
Results
Correlation between influenza-like illness rates and the number of
seasonal influenza isolates during the 2010/11-2013/14 seasons
Based on the weekly reports of influenza activity provided by KCDC [18], we correlated
human ILI incidence rates with the number of typed seasonal influenza cases in Korea (Fig
1). This shows that the ILI incidence rates always peaked between January and March dur-
ing the 2010/11-2013/14 seasons. Unlike the other three seasons, there were two ILI peaks
in the 2011/12 season, which associate with the numbers of H3N2 and IBV isolates, respec-
tively, in a chronological order. Of the three seasonal influenza viruses, the H3N2 virus was
consistently detected in >20% of the typed isolates in the four consecutive seasons (S1
Table), whereas the fluctuation in proportion of H1N1 and IBV cases is more pronounced
(Fig 1), and the persistent circulation of H3N2 appeared to impact the ILI incidence rates in
Korea, especially during the 2011/12 season, as presented in the correlation coefficients (S2
Table).
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Phylogenetically discordant clustering patterns and serological
comparison between the vaccine and Korean H3N2 strains from the
2011/12 season
The evolutionary relationships between the vaccine and contemporary Korean H3N2 strains
were investigated to better understand what might have caused the 2011/12 ILI peak. In the
HA phylogenetic tree (Fig 2A), the KISED sequences of the 2011/12 season separated into
three major Korean clades (Korean HA clade I, light green; Korean HA clade II, violet; and
Korean HA clade III, orange), and the KUMC HAs contributed to the Korean HA clades II
and III. Of the three Korean HA clades, only the clade I HAs belongs to the A/Perth/16/
2009-like A/Victoria/210/2009 (VI210) vaccine virus lineage [41]. In contrast, the clade II and
III HAs clustered into the subgroups of the A/Victoria/208/2009 (VI208) HA lineage (Fig 2A).
Consistently with this observation, the selected KUMC strains, of which HAs were clustered
into the Korean HA clades II and II, showed much lower antibody titers than three vaccine-
related viruses in the HI assay using the post-vaccinated patient sera of the 2011–12 season
(Table 1). Against the three vaccine-related X-187, X-187/HA:T228S, and VI210 viruses, the
sera exhibited 239.88 ± 2.40, 211.12 ± 2.29, and 220.47 ± 2.29 HI titers, respectively. However,
the same sera produced much lower titers (8.41 ± 1.78 to 33.35 ± 1.66) against the 12 selected
KUMC strains, and more than 75 to 96% sera reacted poorly (less than 40 HI titers) (Table 1).
In the NA phylogenetic tree (Fig 2B), none of the Korean taxa clustered with the VI210 vac-
cine strain, either. Rather, the sampled Korean diversity appeared to be more closely related
with the VI208 NA and grouped into three different clades (Korean NA clade I, light green;
Korean NA clade II, violet; and Korean NA clade III, orange). Based on our sequence set, the
clade I NA lineage appeared to evolve from the A/California/VRDL335/2009-like NA, and the
clades II and III NA lineages from the A/California/VRDL347/2009-like NA (Fig 2B).
We could trace reassortment events for some Korean H3N2 strains. The HA and NA
sequences from most isolates clustered in homologous clades, but three of the clade I HAs, two
of the clade II HAs, and four of the clade III HAs clustered discordantly in the NA phylogeny
(Fig 2B). None of these reassortant candidates retained mutations from aspartic acid to glycine
or asparagine at NA residue 151 (D151G or D151N) (S1 Data), which was reported as a molec-
ular signature for NA receptor binding variants of previous seasons [42].
Fig 1. ILI cases and the number of isolates of seasonal influenza viruses in Korea during the 2010/11-
2013/14 seasons. ILI cases per 1,000 patients and the number of isolates of seasonal influenza viruses were
summarized based on the nation-wide weekly surveillance reports of KCDC on seasonal influenza activity in
Korea during the 2010/11-2013/14 seasons. The weekly ILI incidence rates were indicated with black circles
linked with a black solid line, and the weekly number of each viral isolates was indicated with different colors
(for H1N1, light blue; for H3N2, light red; and for human B, light green).
doi:10.1371/journal.pone.0172059.g001
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Different amino acid signatures between the vaccine and Korean H3N2
strains during the 2011/12 season
It had been previously reported that VI208 and the 2011/12 vaccine virus, A/Perth/16/2009
(PE16), are antigenically similar despite the considerable evolutionary divergence between
their HA sequences [43]. There are, however, several indications that the 2011/12 Korean iso-
lates do not per se share their antigenic properties with the VI208 and VI210 strains. Firstly,
most of the amino acid mutations that influenced the differentiation of the three Korean HA
clades from PE16, (Fig 2A) were found in HA antigenic sites, which determine the antigenic
properties of Korean H3N2 strains (site A, K144N and N145S; site B, A198S; site C, S45G/N,
T48I, E50K, and N278K; site D, T212A; site E, K62N, I260M, and R261Q; and others, Q33R
and P162S) (Table 2) [44]. Second, the vaccine strain of the 2012/13 season (A/Victoria/361/
2011 (VI361), which has a discrete antigenic profile from that of PE16 [45], clusters among the
Korean H3N2 strains. This suggests that at least strains from this clade had the potential to
evade the protective immunity raised in response to vaccination with the PE16-like VI210 vac-
cine. As the HA clade III isolates share their mutations in the antigenic sites with the clade II
isolates (site A, K144N; site B, A198S; site D, T212A; and site E, K62E) (Table 2), the latter
likely also exhibit antigenic similarity to VI361 rather than to the VI210 vaccine virus. In the
2012/14 seasons, KUMC strains appeared to harbor the HA gene of the 3C.3a clade (Fig 3A)
and still retained 10 amino acid mutations, compared with the HA sequence of a WHO-rec-
ommended vaccine virus, A/Victoria/361/2011 (VI361). Of these, three mutations (Q33R,
N145S, and N278K) had been already observed from the previous season, but the rest seven
Fig 2. Phylogenetic relationships of the HA and NA genes of Korean H3N2 strains circulating in the 2011/12 season.
The evolutionary relationships of the HA and NA genes of Korean H3N2 strains were reconstructed using the KISED (n = 154)
and KUMC (n = 21) sequences. The sequences downloaded from the NCBI (n = 451) and GISAID (n = 8) databases were
used as references. The three Korean HA and NA clades are indicated with different colors (clade I, light green; clade II,
violet; and clade III, orange), and the KUMC sequences in the clades II and III were highlighted with purple and light red
colors, respectively. The vaccine virus tips (PE16, VI210, and VI361) and the other clade-defining sequences (VI208, A/
California/VRDL335/2009, and A/California/VRDL347/2009) were colored with red and blue, respectively. The KUMC viruses
used for the HI assay were indicated with viral isolate numbers (please see Table 1). In the NA tree, the sequences of
reassortment candidate strains between the HA and NA genes were indicated with a capital letter ‘R’ and the colors of their
corresponding HA clades. Trunk lineage amino acid mutations were also indicated.
doi:10.1371/journal.pone.0172059.g002
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mutations appeared to be newly identified HA mutations (site A, A138S; site B, T128A,
Q156H, F159S, and V186G; and site D, Y219S and N225D) in antigenic sites during the 2012/
14 seasons (Table 2).
Korean clade-related mutations were also found in the NA sequences in the 2011/12 season.
Among the three Korean NA clades (Fig 2B), the highest number of amino acid mutations rel-
ative to the PE16 NA accumulated in clade I lineages (n = 7: D127N, E221K, I307M, I338F,
N342D, N402D, and R430S), and the clades II and III harbored three (L81P, K369T, and
N402D) and five (L81P, D93G, I222V, K369T, and N402D) mutations, respectively (Table 2).
Of these, the I222V mutation identified in the clade III NAs has been associated with oseltami-
vir resistance of H3N2 virus [46]. During the 2012/14 seasons, only the four mutations
Table 1. HI-reactive antibody titers of post-vaccinated patient sera of KUMC Guro Hospital.
Post-vaccinated sera of KUMC patients in the 2011–12 season
Group Virus GMT (± SD)a 95% CIb % ratio of 40 HI titerc
Vaccine X-187 239.88 ± 2.40 199.53–292.12 100 (80/80)
X-187/HA:T228S 211.12 ± 2.29 173.78–251.19 100 (80/80)
VI210 220.47 ± 2.29 181.97–263.03 100 (80/80)
Korea HA clade II KUMC1601 13.08 ± 1.74 11.48–14.79 6.25 (5/80)
KUMC1704 9.02 ± 1.55 8.13–10.00 5.00 (4/80)
KUMC2510 18.5 ± 1.58 16.60–20.42 17.50 (14/80)
KUMC2602 15.69 ± 1.74 13.80–17.78 12.50 (10/80)
KUMC3005 29.03 ± 1.70 25.70–32.36 48.75 (39/80)
KUMC4103 18.18 ± 1.62 16.22–20.42 16.25 (13/80)
Korea HA clade III KUMC0502 8.41 ± 1.78 7.41–9.55 3.75 (3/80)
KUMC2006 16.25 ± 1.91 14.13–18.62 16.25 (13/80)
KUMC3201 14.39 ± 2.00 12.30–16.60 13.75 (11/80)
KUMC3603 33.35 ± 1.66 29.51–37.15 58.75 (47/80)
KUMC6603 20.53 ± 1.74 18.20–23.44 25.00 (20/80)
KUMC8103 10.72 ± 1.91 9.33–12.30 6.25 (5/80)
aGeometric mean titer (GMT) is indicated with standard deviation (SD).
bConfidence interval.
cThe number of serum samples exhibiting more than 40 HI titer is indicated in parenthesis.
doi:10.1371/journal.pone.0172059.t001
Table 2. Amino acid mutations associated with the Korean H3N2 clades.
Amino acid mutation at a given residue
Season Clade HAa NA
2011–
12
I E50K (C), P162S, I260M (E), R261Q (E) D127N, E221K, I307M, I338F,
N342D, N402D, R430S
II S45G (C), K62E (E), K144N (A), N145S (A), A198S (B),
T212A (D)
L81P, K369T, N402D
III Q33R, S45N (C), T48I (C), K62E (E), K144N (A), A198S
(B), T212A (D), N278K (C)
L81P, D93G, I222V, K369T,
N402D
2012–
14
3C.3a Q33R, T128A (B), A138S (A), N145S (A), Q156H (B),
F159S (B), V186G (B), Y219S (D), N225D (D), N278K
(C)
E221D, K258E, T329N, I392T
aHA antigenic sites (A, B, C, D, and E) are indicated in parenthesis.
doi:10.1371/journal.pone.0172059.t002
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(E221D, K258E, T329N, I392T) were found in the NA gene of KUMC strains, compared with
the VI361 NA (Table 2).
We next looked for signatures of positive selection in the HA and NA gene sequences. This
revealed that the HA antigenic site C residues 45 and 261, which associated with the diver-
gence of Korean HA clades, were positively selected. NA residue 81, which was generated just
before the separation of clade II and III lineages, appeared positively selected, also (Table 2).
These may suggest that amino acid mutations in the HA antigenic sites and NA residues and
evolutionary selection pressures working on them had affected the establishment of Korean
H3N2 clades, which might eventually affect fitness differences between the vaccine and Korean
H3N2 strains [25, 47].
Phylogenetic relationships between the vaccine and circulating H3N2
strains during the 2008/09-2013/14 seasons
To investigate whether the ‘vaccine mismatch’ clustering patterns of Korean strains were
unique to the 2011/12 season, we also estimated the evolutionary relationships between the
vaccine and other contemporary H3N2 strains over an extended time frame (2008/09-2013/14
seasons) (Fig 3). Three vaccine viruses had been recommended by the WHO during these peri-
ods: for the 2008/09-2009/10 seasons, A/Brisbane/10/2007 (BR10, dark green); for the 2010/
Fig 3. Clustering patterns of the HA and NA genes between the vaccine and circulating H3N2 strains during the 2008/09-
2013/14 seasons. To compare the phylogenetic clustering patterns of the HA and NA genes between the vaccine and circulating
H3N2 strains, the evolutionary relationships of the HA and NA genes were reconstructed using the genetic sequences of the 2008/
09-2013/14 seasons. The vaccine virus tips (BR10, dark green; PE16 and VI210, light green; and VI361 and TX50, sky blue) and
the 2011/12-2013/14 KUMC sequences are indicated with different colors: for 2011/12, pink; for 2012/13, orange; and for 2013/14,
purple. The tips of clade-defining sequences were colored blue (VI210 and A/Netherlands/034/2010). For the three HA clades,
each representative sequence was indicated with the different number of an asterisk (*, clade 3C.2a, A/Stockholm/29/2014; **,
clade 3C.3b, A/Newcastle/22/2014; and ***, clade 3C.3a, A/South Australia/55/2014), and the same asterisk annotation was
used for the NA of each corresponding strain. The five differentiated NA clades are indicated with NAI, NAII, NAIII, NAIV, and NAV,
respectively.
doi:10.1371/journal.pone.0172059.g003
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11-2011/12 seasons, PE16 (and PE16-like VI210) (light green); and for the 2012/13-2013/14
seasons, VI361 (and A/Texas/50/2012 (TX50)) (sky blue) (Fig 3A and 3B) [43, 45, 48–51].
Even though the HA genes of vaccine viruses were always clustered with a previous clade, the
picture emerges that, in the 2012/13 and 2013/14 seasons, which were characterized by lower
levels of H3N2 cases when compared to the 2011/12 season (Fig 1), the vaccine and sampled
Korean variants are more closely related to each other than in the 2011/12 season. (Fig 3A).
There is no clear relationship between genetic and antigenic distance [20], but the vaccine
update from VC361 to TX50 in the 2013/14 season appeared to decrease antigenic variations
between the vaccine and Korean strains during these seasons. As this coincides with overall
lower counts of H3N2 isolates, it might be said that the ILI peak in the 2011/12 season
appeared to be mainly affected by the antigenic mismatch between the PE16-based vaccine
and Korean H3N2 strains (Fig 1). It is also noteworthy that, contrary to what was seen in the
2011/12 season (Fig 2B), there were no clear discrepancies in the evolutionary distance
between the vaccine and Korean strains in the NA segment history (Fig 3B). However, more
divergent genetic clades were found in the NA than in the HA. Starting from the 2012/13 sea-
son, three main HA clades (3C.2a, 3C.3a, and 3C.3b) co-circulated until 2014 (Fig 3A). In the
same time frame, there were five main NA clades (NAI, NAII, NAIII, NAIV, and NAV) (Fig 3B).
That all the 2012/13-2013/14 KUMC HA sequences belong to the 3C.3a HA clade, but that
they associated with the NAII and NAV clades (Fig 3A and 3B) indicates a number of reassort-
ment events previously occurred, similar to what was seen in the 2011/12 season (Fig 2B). All
combined, our results indicate that phylogenetic discordant patterns have continuously been
observed in the HA and NA genes between the vaccine and circulating H3N2 strains for the
2008/09-2013/14 seasons and that not only the HA genetic clade but also the NA should be
accounted for in selecting influenza vaccine viruses.
Discussion
Recent methodological advancements have placed phylogenetic inference in the spotlight as a
promising tool for evaluating the antigenic evolution of influenza viruses from the genetic
data. Unlike the classical HI assay, which uses post-infection animal and/or human antisera,
phylogenetic analyses can capitalize on easier to generate, and hence more abundantly avail-
able data to achieve high prediction accuracy [52]. In this study, to explain the H3N2-driven
increases of ILI incidence rates in Korea, we determined the evolutionary relationships of
H3N2 HA and NA genetic sequences, the two main antigenic determinants of influenza
viruses [26, 53]. Contrary to our thoughts, however, it was revealed that the HA and NA genes
of the WHO-recommended vaccine viruses were all clustered into one of the various branches
in previous seasons, not together with those of circulating strains in the corresponding vaccine
seasons (Figs 2 and 3). These phylogenetic discordant clustering patterns between vaccine and
circulating H3N2 strains (Figs 2 and 3) were supported by serological assay results. In the HI
assay, the post-vaccinated patient sera exhibited less than 40 HI-reactive antibody titers against
the selected KUMC strains, compared with the high HI titers against the vaccine-related
viruses (Table 1). Based on these, vaccine effectiveness against H3N2 might be assumed so
poor that the increases of ILI incidence rates appeared to be unavoidable during the 2011/12
season. Consistent with this observation, several reports of reduced vaccine effectiveness
against the H3N2 virus have been reported from Asia, Europe, and North America [54–56]
and even from Korea [15]. As demonstrated by the positive correlation between the ILI inci-
dence rates and the number of H3N2 isolates (Fig 1 and S2 Table), the phylogenetic clustering
patterns of the HA and NA genes might substantiate its significance with regard to the com-
prehensive process of vaccine virus selection.
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In fact, a phylogenetically discordant clustering pattern had been already noticed between
the HAs of PE16 and VI208 [43]. However, the HI assay results probably tipped the balance in
favor of PE16 in the upcoming 2011/12 season [43]. For all that, the mutations in the three
antigenic sites, such as K62E in site E, K144N in site A, and T212A in site D, which would be
remarked between the HAs of PE16 and VI208, should have been considered for their poten-
tial effects on the change of viral antigenic properties (Table 2). In addition, of these three
mutations, K144N was the one that could introduce N-linked glycosylation around the recep-
tor binding site in the HA globular head region (S1 Fig). Given the effects of N-linked glycosyl-
ation on the antigenic property of influenza viruses [39, 57], the K144N mutation might
transform viral antigenicity, and, a heavy glycan side chain anchored at residue 144 would
probably interfere antibody binding targeting around this region, which would eventually
skew overall HI assay results, in a biophysical perspective of HA binding to cellular receptor
sialic acids. Moreover, the Korean H3N2 HA clade III viruses might harbor one more N-
linked glycosylation in the antigenic site C residue 45 by a S45N mutation (Table 2).
Even though the mutation rates of the HA and NA genes in our study cannot be said higher
than those of previous seasons (Table 3) [58], on-going genetic evolution that had been accu-
mulated in circulating H3N2 strains since the WHO vaccine recommendation made in Febru-
ary 2011 might deepen the antigenic disparity between the vaccine and circulating H3N2
strains in the 2011/12 season. Currently, the recommendation of vaccine viruses is usually
made at least six months prior to the corresponding influenza season to ensure that vaccine
manufacturers can have enough time to prepare actual multivalent vaccines by securing the
growth and immunogenicity of the vaccine viruses [59]. However, in the meantime, while the
vaccines are being produced, many mutations can be accumulated, or a novel strain may
newly appear. The replacement of previously circulating strains with this antigenically new
strain may cause a situation such as the case of 2009 swine-origin H1N1 pandemic [60, 61]. In
this case, the vaccines should be updated to meet the antigenicity of a novel strain, and this
may cause a delay of vaccination schedules against seasonal influenza viruses. Otherwise, the
vaccines are unlikely to provide optimal effectiveness in the end. Hence, to ensure that all the
possible seasonal variants at a certain season are to be tested by both serological and phyloge-
netic clustering pattern evaluation, a current system of vaccine production using fertile
chicken eggs should be reconsidered to reduce a vaccine production period and to remove a
setback of egg-adaptive mutations [5, 62, 63].
The NA is one of the two main antigenic determinants [26, 27, 53]. However, for the time
being, the NA clade is not considered in the process of vaccine virus selection. If it had been
considered, PE16 should have been never listed as a vaccine virus because all the Korean NA
sequences in the 2011/12 season constituted subgroups under the VI208 NA, not under the
PE16 NA (Fig 2B). Considering the persistently circulating HA and NA clades until 2014 (Fig
3B), it was again apparent why the NA clade should be taken into account for the selection of
Table 3. Evolutionary rates and selection profiles determined with the HA and NA genes of H3N2 strains circulating for the 2009/10-2011/12
seasons.
Evolutionary rate (x 10−3 substitution/site/year)a Selection profiles
Gene Nucleotide Synonymous Nonsynonymous dN/dS # of positive selection site
HA 4.84 ± 0.47 2.34 ± 0.02 2.15 ± 0.02 0.354 2 (45, 261)b
NA 3.87 ± 0.31 2.27 ± 0.01 1.42 ± 0.01 0.269 3 (44, 81, 151)
aStandard deviation of evolutionary rates is indicated with ‘± values’.
bPositive selection residues (H3N2 numbering) are indicated in parenthesis.
doi:10.1371/journal.pone.0172059.t003
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influenza vaccine viruses. Compared with the three HA clades (3C.2a, 3C.3a, and 3C.3b) (Fig
3A), the five NA clades (NAI, NAII, NAIII, NAIV, and NAV) had evolved until 2014, and these
might suggest the effects of various NA clades on the antigenic evolution of recent H3N2
strains, as indicated in the potential reassortment events between the HA and NA genes in
some of 2011/12 Korean strains (Fig 2B). Indeed, the HAs of 3C.2a and 3C.3a clades appeared
to be coupled with the NAII clade NA (Fig 3B). Considered all together, our results suggest the
importance of not only the HA phylogenetic clade but also the NA one with regard to the
selection of vaccine viruses and the estimation of vaccine effectiveness along with the serologi-
cal HI assay.
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S1 Fig. Structural representation of HA amino acid mutations and the sequons of potential
N-linked glycosylation at HA residues 45 and 144. (A) Based on the amino acid sequence of
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